A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

Enrolling by invitation · Phase 1 · Has a placebo group

Conditions studied: Familial Erythromelalgia

In brief

The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.

Key facts

Study ID

NCT07262268

Run by

Biohaven Therapeutics Ltd.

People needed

5

Starts

2026-01-15

Expected to finish

2026-11-01

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Site-001 — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.